Determinants and Characteristics of Insulin Dose Requirements in Children and Adolescents with New-Onset Type 1 Diabetes: Insights from the INSENODIAB Study
Table 3
ANOVA testing for partial remission outcomes.
M3
M12
76
46
HIS
NIS
IR
value±
HIS
NIS
IR
value±
(%)
13 (17.1)
12 (15.7)
51 (67.1)
9 (19.6)
7 (15.2)
30 (65.2)
IDAA1C
7.2 (1.6)
8.7 (1.6)
8.4 (0.3)
0.052
8.7 (2.4)
10.4 (2.9)
9.2 (1.9)
0.4
remitters (%) ()
10 (76.9)
8 (66.7)
33 (64.7)
5 (55.6)
2 (28.6)
14 (46.7)
TIDD (IU/kg/d)
0.3 (0.1)
0.6 (0.2)
0.6 (0.3)
0.01
0.6 (0.4)
0.8 (0.4)
0.6 (0.3)
0.4
0
0
3 (5.8)
2 (22.2)
2 (28.6)
2 (6.7)
HbA1C (%)
6.0 (1.1)
6.4 (0.6)
6.2 (0.6)
0.6
7.1 (1.0)
6.5 (1.7)
6.6 (1.3)
0.7
CPEPEST (pmol/mL)
0.7 (0.3)
0.5 (0.5)
0.5 (0.3)
0.2
0.5 (0.2)
0.3 (0.3)
0.3 (0.4)
0.2
(%)
12 (92.3)
10 (83.3)
34 (66.7)
8 (88.9)
4 (57.1)
20 (66.7)
Legend: values are median and IQR. Percentages may not total to 100 because of rounding. ±One-way ANOVA testing; value is considered significant if < 0.05. Abbreviations: IDAA1C = insulin-dose adjusted A1C; TIDD = insulin total daily dose; HbA1C = glycated hemoglobin level; CPEPEST = estimated C-peptide; NA = not applicable.
